A Phase I Dose Escalation Study of Lipopeptide Vaccines With Activity Against Human Cytomegalovirus

NCT00712634 Phase 1 COMPLETED

RATIONALE: Vaccines may help the body build an effective immune response against cytomegalovirus. PURPOSE: This randomized phase I trial is studying the side effects and best dose of cytomegalovirus vaccine in healthy participants.

Details

Lead sponsor	City of Hope Medical Center
Phase	Phase 1
Status	COMPLETED
Enrolment	46
Start date	1997-11
Completion	2009-04

Conditions

• Precancerous/Nonmalignant Condition

Interventions

• CMVpp65-A*0201 peptide vaccine

Primary outcomes

• Safety and toxicity
• Immunologic response
• Duration of immunologic response

Countries

United States